Twist Bioscience Corporation (TWST)
| Market Cap | 2.88B |
| Revenue (ttm) | 391.56M |
| Net Income (ttm) | -76.58M |
| Shares Out | 61.31M |
| EPS (ttm) | -1.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 774,785 |
| Open | 47.47 |
| Previous Close | 48.71 |
| Day's Range | 46.06 - 48.11 |
| 52-Week Range | 23.30 - 57.88 |
| Beta | 2.27 |
| Analysts | Buy |
| Price Target | 48.75 (+3.9%) |
| Earnings Date | Feb 2, 2026 |
About TWST
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]
Financial Performance
In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $48.75, which is an increase of 3.90% from the latest price.
News
Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript
Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement wi...
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twis...
Twist Bioscience: Liquid Biopsy And AI Tailwinds
Twist Bioscience's stock has moved high in recent months, driven by optimism related to AI-enabled drug discovery and MRD testing. Q1 growth was modest, due in large part to an air pocket in demand ca...
These Analysts Increase Their Forecasts On Twist Bioscience After Q1 Results
Twist Bioscience Corporation (NASDAQ: TWST) on Monday posted better-than-expected sales for the first quarter.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value bi...
Why Is Twist Bioscience Stock Soaring Monday?
Twist Bioscience Corporation (NASDAQ: TWST) on Monday posted first-quarter 2026 results of a loss of 50 cents per share, in line with the Wall Street expectations.
Twist Bioscience: Ingenious Product Still Lacks Compelling Use Cases
Twist Bioscience Corporation reported Q1 2026 revenue of $103.7M, up 17% YoY, and raised full-year guidance to $435–$440M. TWST targets adjusted EBITDA breakeven in Q4 2026, with gross margin expected...
Twist Bioscience Corporation (TWST) Q1 2026 Earnings Call Transcript
Twist Bioscience Corporation (TWST) Q1 2026 Earnings Call Transcript
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...
Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quar...
Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciar...
Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to suppo...
Twist Bioscience Is Bent, Not Broken: Near-Term Strain, Long-Term Strength
Twist's revenue growth continues to moderate due to macro headwinds and temporary challenges in the NGS business. The Biopharma segment is reaccelerating, though, driven by AI-enabled drug discovery c...
Can Twist Bioscience Drop More?
Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but signifi...
Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript
Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript
Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses
Twist Bioscience Corporation (NASDAQ: TWST) on Friday posted mixed fourth-quarter results, reporting a loss of 45 cents per share, slightly wider than the consensus estimate of a 43-cent loss.
Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...
Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings
Twist Bioscience Corporation (NASDAQ: TWST) will release fourth-quarter earnings before the opening bell on Friday, Nov. 14.
Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Twist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the ...
Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ System
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, and Element Biosciences, Inc., a company democratizin...